BioPhoenix Co

Research & Development

BioPhoenix is composed of a team of seasoned professionals with deep expertise in technology R&D and evaluation, market and industry analysis, intellectual property strategy and licensing, clinical trials, and regulatory review for new drug approvals. Through its Leverage Research Co-Development (LRCD) innovation model, the company strategically integrates and leverages domestic and international R&D resources across three critical dimensions: target selection, development, and commercialization. This approach accelerates the advancement of novel mechanism-based First-in-Class or Best-in-Class small-molecule new chemical entities (NCEs) that address unmet medical needs in the world’s three major therapeutic areas. BioPhoenix is committed to delivering effective treatment solutions and contributing to the advancement of global health.

Core Competence

Maximizing Impact and Minimizing Risk Through Integrated Expertise.
Our multidisciplinary team strategically integrates resources to optimize efficiency and reduce the risks associated with new drug development.

Evaluation of drug technologies, intellectual property, market potential, and competitive landscape.

Preclinical pharmacokinetic / pharmacodynamic / Toxicological (PK/PD/Tox) research, clinical trial design and execution, and regulatory submission for new drug registration.

Licensing negotiations, strategy development, and project execution.

Immunology

Estimated 10% of total population suffer from autoimmune diseases

The immune system plays a vital role in protecting the human body from both external and internal threats. When the immune system becomes dysregulated—whether through immunodeficiency, autoimmune attacks on the body's own tissues, or hypersensitivity leading to allergic reactions, it becomes a major contributor to disease. Studies estimate that approximately 10% of the global population³suffers from autoimmune diseases, and allergic conditions are also widespread. The World Health Organization (WHO) projects that by 2050, one in every two people may be affected by some form of allergic disease⁴.

Oncology

Every minute, 37 people are newly diagnosed with cancer

Cancer is a leading cause of death and disability worldwide. According to the World Health Organization (WHO), there were 19.3 million new cancer cases and nearly 10 million cancer-related deaths globally in 2020 ^5,6. It is estimated that 1 in 5 people will be diagnosed with cancer during their lifetime. By 2040, the number of new cancer cases is projected to increase by 47%, underscoring the urgent and growing need for effective treatments.

Ophthalmology

At least 2.2 billion people facing vision complications

A WHO study¹report points out that, global vision problems are becoming increasingly severe due to aging populations and widespread use of digital devices. Statistics show that over 2.2 billion people worldwide suffer from vision impairment or blindness, with the blind population reaching 43 million in 2020. Individuals who live long enough will develop at least one eye disease in their lifetime².